Fusion Pharmaceuticals resumed with a Buy at B. Riley

B. Riley analyst Yuan Zhi resumed coverage of Fusion Pharmaceuticals with a Buy rating and $10 price target. Fusion is a clinical-stage radiopharmaceutical company leading the targeted alpha therapy with actinium-225, Zhi tells investors in a research note. The analyst says the radiopharma field is drawing investors’ attention with the success of Xofigo and Lutathera and the recent launch of Pluvicto. Zhi believes Fusion "represents a top pick in radiopharma players."